94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1564834
Transformative Potential of Trastuzumab Deruxtecan in the First Line Treatment for Advanced HER2-Mutated Lung Adenocarcinoma: A Case Report and Clinical Insights
Provisionally accepted- Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The treatment of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), represents a significant oncological challenge due to its aggressive behavior, high metastatic potential and poor prognosis. HER2 mutation is a rare but critical oncogenic driver associated with resistance to traditional therapies among NSCLC subtypes, including chemotherapy and tyrosine kinase inhibitors (TKIs). Trastuzumab deruxtecan (T-DXd), a next-generation antibody-drug conjugate, combines HER2-targeted therapy with a potent cytotoxic payload, enabling specific tumor cell eradication and addressing intratumoral heterogeneity through its bystander effect. This case report details the treatment of a 69-year-old male with advanced HER2 exon 20-mutant LUAD and widespread metastases. Following the family's refusal of chemotherapy, T-DXd was initiated, leading to prolonged disease stabilization over 14 treatment cycles, demonstrating a progression-free survival of at least 13 months. Imaging assessments revealed a consistent reduction in the primary lung lesion size, with stable disease (SD) observed according to RECIST criteria. Despite a mixed response in brain metastases, T-DXd demonstrated a favorable safety profile without significant adverse events. While pivotal trials such as DESTINY-Lung02 and DESTINY-Lung05 have demonstrated robust efficacy and survival benefits of T-DXd as subsequent lines of therapy, our patient's tolerance and sustained SD support the therapeutic potential of T-DXd as a first line treatment in certain real-world scenarios. In addition, this case reinforces the importance of molecular profiling in guiding personalized treatment strategies and highlights the need for further research, particularly in overcoming challenges related to central nervous system metastases. Overall, T-DXd represents a promising advancement in HER2-mutant NSCLC management, offering hope for improved outcomes in this underserved patient population.
Keywords: HER2-mutant NSCLC, trastuzumab deruxtecan, Antibody-drug conjugate, First line treatment, Central nervous system metastases
Received: 22 Jan 2025; Accepted: 26 Mar 2025.
Copyright: © 2025 Huang, Xia, Yang, Lin, Luo, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hualin Chen, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.